Diabetes care product company ARKRAY USA Inc reported on Monday the launch of newest blood glucose monitoring system (BGMS) in the US, the GLUCOCARD Shine XL.
According to the company, the GLUCOCARD Shine XL blood glucose monitoring system is now available for order in the US.
Highly accurate with a large LED screen intended to facilitate quick and easy viewing of blood glucose test results, the GLUCOCARD Shine XL BGMS offers an ergonomically designed meter that provides a secure grip during testing as well as uses the same test strips as the prior GLUCOCARD Shine, which has been proven to provide highly accurate test results in an easy to use form.
ARKRAY USA Inc, which is a division of ARKRAY headquartered in Kyoto, Japan, currently does business in more than 80 countries worldwide and is the market leader in diabetes management in the long-term care market in the US.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies